Peck Hannah, Pagani Wilfredo, Smith Arianna, Madhavan Srivats
Medical College of Wisconsin, Milwaukee, WI.
Division of Gastroenterology and Hepatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
ACG Case Rep J. 2025 Apr 3;12(4):e01653. doi: 10.14309/crj.0000000000001653. eCollection 2025 Apr.
One to 2% of patients undergoing immune checkpoint inhibitor (ICI) therapy develop ICI-induced pancreatitis (ICI-IP). A small subset of these patients develop recurrent pancreatitis, even after discontinuation of ICI therapy. This case series presents 2 patients with recurrent steroid-responsive ICI-IP who were managed with immunomodulators as steroid-sparing agents. Both patients were maintained on immunomodulators for approximately 2 years before discontinuation of the agents, with no further recurrence or complications of pancreatitis. This case series highlights the use of mycophenolate mofetil and azathioprine for the management of recurrent ICI-IP.
接受免疫检查点抑制剂（ICI）治疗的患者中有1%至2%会发生ICI诱导的胰腺炎（ICI-IP）。这些患者中有一小部分会发生复发性胰腺炎，即使在停用ICI治疗后也是如此。本病例系列介绍了2例复发性类固醇反应性ICI-IP患者，他们使用免疫调节剂作为类固醇节约剂进行治疗。两名患者在停用药物前均接受免疫调节剂治疗约2年，胰腺炎未再复发或出现并发症。本病例系列强调了霉酚酸酯和硫唑嘌呤在复发性ICI-IP治疗中的应用。
